15763 Results

People

  1. Hudis
    Hudis
  2. Offit
    Offit
  3. Zelefsky
    Zelefsky
  4. Giralt
    Giralt
  5. Robson
    Robson
  6. Yahalom
    Yahalom
  7. Wolden
    Wolden
  8. Coit
    Coit
  9. Marghoob
    Marghoob
  10. Tuttle
    Tuttle

Groups

  1. Survivorship Research (15763)
  2. Department of Medicine (9202)
  3. Population Sciences Research Program (5670)
  4. Solid Tumor Oncology Division (5184)
  5. Surgery (5131)
  6. Epidemiology and Biostatistics (3598)
  7. Division of Subspecialty Medicine (3242)
  8. Center for Hematologic Malignancies (2610)
  9. Biostatistics Service (2488)
  10. GSK Faculty (2413)
  1. "Survivorship Research"
Formats
  1. Journal Article (8900)
  2. Meeting Abstract (5192)
  3. Book Section (571)
  4. Review (357)
  5. Editorial (225)
  6. Research Letter (132)
  7. Conference Paper (104)
  8. Correspondence (91)
  9. Guidelines (85)
  10. Miscellaneous (76)
  11. Book Whole (30)
Groups
  1. Survivorship Research (15763)
  2. Department of Medicine (9202)
  3. Population Sciences Research Program (5670)
  4. Solid Tumor Oncology Division (5184)
  5. Surgery (5131)
  6. Epidemiology and Biostatistics (3598)

More Groups

People
  1. Clifford Hudis (905)
  2. Kenneth Offit (788)
  3. Michael Zelefsky (754)
  4. Sergio Giralt (684)
  5. Mark Robson (676)
  6. Joachim Yahalom (625)

More People

Years
  1. 2025 (231)
  2. 2024 (802)
  3. 2023 (892)
  4. 2022 (906)
  5. 2021 (922)
  6. 2020 (930)

More Years

Publications
  1. Journal of Clinical Oncology (1873)
  2. International Journal of Radiation Oncology, Biology, Physics (908)
  3. Blood (685)
  4. Annals of Surgical Oncology (599)
  5. Cancer Research (333)
  6. Cancer (331)

More Publications

Publishers
  1. Elsevier Inc. (2658)
  2. American Society of Clinical Oncology (2019)
  3. Springer (1542)
  4. Wiley Blackwell (806)
  5. Oxford University Press (787)
  6. American Society of Hematology (748)

More Publishers

Results (15763)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adjuvant cytotoxic chemotherapy may not be associated with a survival advantage for resected intrahepatic cholangiocarcinoma
    Journal Article

    Sharib, J.; Rhodin, K. E.; Liu, A.; McIntyre, S.; Bartholomew, A.; Masoud, S.; DeLaura, I.; Kemeny, N. E.; Cercek, A.; Harding, J. J.; more...
    Annals of Surgical Oncology (2025)

    Fulltext@MSK | Save
  • Higher risk renal angiomyolipomas: Surveillance remains a safe management option
    Journal Article

    Dawidek, M. T.; Villada, J. S. A.; Vazquez-Rivera, K.; Fuchs, H.; Calderon, L. P.; Eismann, L.; Reese, S. W.; Ganz, M.; Ridouani, F.; Ostrovnaya, I.; more...
    Urology Practice (2025)

    Fulltext@MSK | Save
  • Drivers of job loss among Chinese breast cancer survivors: A Qualitative Analysis
    Journal Article

    Chimonas, S.; Sampathkumar, Y.; Huang, X.; Tran, C.; Wang, Z.; Kuo, T. T.; Rosenberg, S. M.; González, J.; Gany, F.; Blinder, V.
    Psycho-Oncology (2025)

    Fulltext@MSK | Save
  • Spaceflight Associated Neuro-ocular Syndrome (SANS) and its countermeasures
    Review

    Nguyen, T.; Ong, J.; Brunstetter, T.; Gibson, C. R.; Macias, B. R.; Laurie, S.; Mader, T.; Hargens, A.; Buckey, J. C.; Lan, M.; more...
    Progress in Retinal and Eye Research (2025)

    Fulltext@MSK | Save
  • The duration of immunotherapy for mismatch repair-deficient cancers
    Research Letter

    Rousseau, B.; White, J. R.; Cercek, A.; Diaz, L. A. Jr
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • ISIC 2024 preface
    Editorial

    Celebi, M. E.; Barata, C.; Halpern, A.; Tschandl, P.; Combalia, M.; Liu, Y.; Celebi, M. E.; Chen, Z.; Reyes, M.; Li. X.
    Medical Image Computing and Computer Assisted Intervention – MICCAI 2024 Workshops (2025)

    Fulltext@MSK | Save
  • Reply by authors
    Correspondence

    Tallman, J. E.; Vertosick, E. A.; Alam, S. M.; Baky, F. J.; Donat, S. M.; Pietzak, E. J.; Cha, E. K.; Donahue, T. F.; Bochner, B. H.; Vickers, A. J.; more...
    Journal of Urology (2025)

    Fulltext@MSK | Save
  • Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: Clinical insights and genomic features from a large contemporary cohort
    Journal Article

    Keane, F.; O’Connor, C.; Moss, D.; Chou, J. F.; Perry, M. A.; Crowley, F.; Saxena, P.; Chan, A.; Schoenfeld, J. D.; Singhal, A.; more...
    JNCI: Journal of the National Cancer Institute (2025)

    Fulltext@MSK | Save
  • Response to Hu, Yang, and Sun
    Correspondence

    de Lima, P. N.; Rutter, C. M.; van den Puttelaar, R.; Hahn, A. I.; Ozik, J.; Collier, N.; Zauber, A. G.; Lansdorp-Vogelaar, I.; Inadomi, J. M.
    JNCI: Journal of the National Cancer Institute (2025)

    Fulltext@MSK | Save
  • Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma
    Journal Article

    Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save